Fact-checked by Grok 2 weeks ago

Atrial flutter

Atrial flutter is a common supraventricular characterized by rapid, organized electrical activity in the atria, typically at a rate of 250 to 350 beats per minute, resulting in a coordinated but abnormally fast heartbeat in the heart's upper chambers. This condition, often classified as a macro-reentrant , differs from the more chaotic but shares similarities, including the potential for the ventricles to respond at a slower rate of 150 beats per minute due to conduction blocks. It is the second most prevalent cardiac after and can occur in isolation or alongside other heart rhythm disorders. Many individuals with atrial flutter experience no symptoms and may only discover the condition during routine medical examinations, but when present, symptoms often include , a sensation of fluttering or pounding in the chest, , , , and . More severe manifestations can involve , fainting (syncope), anxiety, weakness, or even signs of such as or jugular venous distension, particularly if the leads to rapid ventricular rates or reduced . These symptoms arise because the overly rapid atrial contractions impair the heart's ability to fill properly with blood, potentially leading to complications like , , or chronic if untreated. The primary cause of atrial flutter involves disruptions in the heart's electrical conduction system, often due to a re-entry circuit where electrical impulses loop repeatedly through the atria, facilitated by areas of slow conduction and anatomical barriers such as the cavotricuspid isthmus in typical cases. Common triggers include underlying heart conditions like , , , or congenital defects, as well as non-cardiac factors such as chronic obstructive pulmonary disease (COPD), , thyroid disorders, or recent heart surgery. Risk factors encompass advancing age, male sex, , , excessive alcohol consumption, and a history of , with the arrhythmia being more prevalent in older adults and those with structural heart disease. Atrial flutter is broadly categorized into typical (cavotricuspid isthmus-dependent, often involving the right atrium) and atypical (independent of the isthmus, frequently linked to left atrial circuits or prior interventions like ablation), with typical forms being more amenable to curative catheter ablation procedures. Diagnosis typically relies on electrocardiography (ECG), which reveals characteristic "sawtooth" flutter waves, while management focuses on rate control, rhythm restoration via cardioversion or medications, anticoagulation to prevent thromboembolism, and ablation for long-term resolution. Early intervention is crucial, as untreated atrial flutter increases the risk of systemic embolization and progression to more persistent arrhythmias.

Background

Definition and Classification

Atrial flutter is a characterized by rapid, organized atrial contractions due to a macro-reentrant within the atria, typically producing an atrial rate of 250 to 350 beats per minute and distinctive sawtooth flutter waves on (ECG). This arrhythmia arises from a single, stable reentrant loop that propagates electrical impulses in a circular fashion, leading to coordinated but excessively fast atrial activity. Unlike other supraventricular rhythms, the ventricular response is often regular and determined by atrioventricular () nodal conduction ratios, such as 2:1 block, resulting in a ventricular rate around 150 beats per minute. Atrial flutter differs from , another common supraventricular , in that it features highly organized, regular atrial depolarizations rather than the chaotic, irregular electrical activity seen in fibrillation. In flutter, the atrial wavefront maintains a consistent pathway, producing uniform flutter waves on ECG, whereas fibrillation involves multiple disorganized wavelets across the atria. Atrial flutter is classified into typical (Type I) and atypical (Type II) forms based on the location and dependence of the reentrant . Typical flutter, the most common variant, is cavotricuspid (CTI)-dependent and involves a macro-reentrant in the right atrium, with either counterclockwise (most frequent) or rotation around the tricuspid annulus. flutter, in contrast, is non-CTI-dependent and often arises from circuits in the left atrium or scar-related areas due to prior or , requiring electrophysiologic mapping for precise identification. The condition was first recognized in the early through ECG recordings, with Sir Thomas Lewis and colleagues describing the reentrant mechanism in animal models around 1920-1921, coining the term "flutter" for the rapid, regular atrial contractions observed.

Epidemiology

Atrial flutter has an estimated annual incidence of approximately 200,000 new cases , representing a significant but often underrecognized portion of supraventricular arrhythmias compared to the far more prevalent .00982-7) This figure is extrapolated from population-based studies and highlights atrial flutter's contribution to cardiovascular morbidity, though global estimates are challenging due to frequent grouping with in epidemiological data. The of atrial flutter increases markedly with , remaining rare in individuals under years (incidence approximately 5 per 100,000) and peaking in those over 70 years, where rates can exceed 200 per 100,000.00982-7) It is approximately twice as common in males as in females, with a male-to-female of about 2:1, potentially influenced by differences in underlying structural heart disease.00982-7) Geographic variations in atrial flutter incidence are notable, with higher rates observed in developed countries attributable to aging populations and increased of comorbidities such as . For instance, high sociodemographic index regions exhibit elevated age-standardized incidence rates compared to lower-income areas, driven by longer life expectancies and better diagnostic access. Atrial flutter frequently coexists with or progresses to , with studies reporting concomitant episodes in up to 58% of cases and long-term progression rates around 50-60%.00982-7) This association underscores the shared risk profiles and the potential for atrial flutter to serve as a precursor in a substantial proportion of patients.

Etiology and Pathophysiology

Risk Factors and Causes

Atrial flutter often arises in the context of underlying structural heart disease, which creates substrates for reentrant circuits. Common primary causes include post-surgical scars from cardiac procedures such as valve replacements or congenital heart repairs, which can form fixed barriers promoting atypical flutter. and are also significant contributors, each affecting approximately 30% of cases, through mechanisms like atrial ischemia and dilation. , particularly rheumatic involvement, is also a significant contributor by causing atrial enlargement and . Pulmonary conditions further predispose individuals, with (COPD) increasing risk through right atrial strain and hypoxia, and triggering acute episodes via hemodynamic stress. Modifiable risk factors play a key role in the development of atrial flutter by promoting atrial remodeling. is a leading factor, affecting up to 30% of cases through left atrial dilation and increased . Diabetes mellitus contributes via metabolic changes that exacerbate and in the atria. heightens susceptibility by inducing and sleep apnea-related , while excessive consumption can provoke acute episodes through direct toxic effects on cardiac conduction. accelerates atrial rates by elevating sympathetic tone and altering electrolyte balance. Non-modifiable risk factors include advanced age, which correlates with progressive atrial fibrosis and conduction abnormalities, with prevalence rising sharply after 65 years. Male sex is associated with higher incidence, potentially due to hormonal influences on atrial , accounting for about 75% of cases in some cohorts. Congenital heart defects, such as atrial septal defects, provide inherent substrates for reentry even after correction. A family history of arrhythmias indicates , linked to variants in genes like PITX2 that affect atrial development. Inflammation and are central to atrial remodeling that heightens vulnerability to . Chronic , driven by and leukocyte infiltration, promotes activation and deposition, leading to heterogeneous conduction. disrupts normal atrial architecture, creating zones of slow conduction that facilitate reentrant circuits, particularly in the presence of comorbidities like or aging. These processes form a persistent substrate, increasing the likelihood of sustained atrial .

Pathophysiological Mechanisms

Atrial flutter is primarily sustained by a macro-reentrant mechanism involving a large in the right atrium, where an electrical wavefront circulates around fixed anatomical obstacles such as the tricuspid annulus and . In typical atrial flutter, the cavotricuspid isthmus—a narrow region between the and —serves as a critical zone of slowed conduction, allowing the impulse to propagate unidirectionally while the rest of the atrium recovers excitability. This reentry requires an initial unidirectional block, often at the or eustachian ridge, to direct the wavefront into the isthmus and prevent short-circuiting, with the slowed conduction in this area enabling the circuit to complete a full in approximately 200-250 milliseconds. The atrial activation during flutter results in regular, rapid at rates of 250-350 beats per minute, producing a sawtooth pattern of continuous electrical activity without distinct isoelectric intervals. Due to the atrioventricular () node's inherent conduction properties, a 2:1 AV block commonly occurs, yielding a ventricular rate of around 150 beats per minute, though variable block (e.g., 3:1 or 4:1) can lead to irregularity. Hemodynamically, atrial flutter impairs by eliminating the "atrial kick"—the coordinated atrial contraction that contributes 20-30% to ventricular filling—resulting in reduced preload and . The rapid ventricular rates further disrupt diastolic filling time, exacerbating irregular ventricular contraction and potentially leading to tachycardia-induced with prolonged episodes, characterized by left ventricular dysfunction and symptoms. Transition from atrial flutter to atrial fibrillation often occurs via the wavelength theory, where a shortened atrial period or reduced conduction decreases the excitation —the product of refractory period and conduction velocity—allowing the stable macro-reentrant to fragment into multiple, self-sustaining wavelets that sustain fibrillatory conduction. This shift is facilitated by underlying atrial remodeling, such as or alterations, which promote heterogeneous refractoriness and enable the breakdown of organized reentry into chaotic activity.

Clinical Presentation

Signs and Symptoms

Atrial flutter often manifests as paroxysmal episodes that are self-terminating within 7 days, persistent episodes lasting more than 7 days that typically require medical intervention to terminate, or permanent cases representing a , ongoing rhythm disturbance. Common patient-reported symptoms during episodes include —a fluttering, pounding, or racing sensation in the chest—along with , or , , and chest discomfort. These symptoms arise from the rapid atrial contractions, which can lead to irregular ventricular responses and reduced cardiac efficiency. The intensity of symptoms correlates with the ventricular rate, where faster rates (often 150 beats per minute or higher due to common 2:1 atrioventricular conduction) exacerbate manifestations such as severe fatigue, , , or even syncope. A significant proportion of cases, up to 30%, occur asymptomatically, particularly among elderly patients or those with adequate ventricular rate control through medication, allowing the condition to go unnoticed until detected incidentally.

Physical Examination Findings

During physical examination of patients with atrial flutter, the peripheral is typically regular or irregularly regular, reflecting the variable atrioventricular () conduction that allows some atrial impulses to reach the ventricles while others are blocked. The ventricular rate is often rapid, commonly ranging from 100 to 175 beats per minute, with a frequent approximation of 150 beats per minute due to consistent 2:1 block, though rates as low as 75 beats per minute or higher may occur depending on intrinsic AV nodal properties or medications. Inspection and palpation of the jugular venous pulse may reveal rapid venous pulsations corresponding to the atrial flutter rate, often appearing as fine, undulating "f" waves rather than distinct a-waves, due to the ineffective and rapid atrial contractions that fail to produce prominent atrial filling. In cases of associated or , jugular venous distension may be evident, signaling underlying hemodynamic compromise. Auscultation of the heart frequently discloses a rapid rhythm, with the intensity of the first heart sound (S1) potentially varying if AV conduction is irregular, though it remains consistent in stable 2:1 block scenarios. Additional auscultatory findings may include murmurs indicative of valvular abnormalities, such as tricuspid or mitral regurgitation, which can coexist with atrial flutter as contributing etiologies. Signs of underlying systemic conditions are often apparent, including lower extremity edema and from congestive heart failure, or bibasilar crackles on lung auscultation due to pulmonary congestion. may detect an enlarged suggesting as a precipitant, while assessment of the point of maximum impulse could reveal lateral displacement in cases of .

Diagnosis

Electrocardiographic Findings

Electrocardiographic findings are central to diagnosing atrial flutter, revealing characteristic atrial activity that distinguishes it from other supraventricular tachycardias. The hallmark is the presence of regular flutter (F) waves, which represent organized atrial at a rapid rate, typically without an isoelectric baseline between them. In typical cavotricuspid (CTI)-dependent atrial flutter, the atrial rate is 250-350 beats per minute, manifesting as continuous undulations on the surface ECG. The classic pattern in counterclockwise typical flutter features a "sawtooth" appearance of F waves, with prominent negative deflections in the inferior leads (II, III, aVF), often described as resembling a due to their sharp downward slopes. These waves are typically low-amplitude and flat in lead I, upright in aVL, and positive or biphasic in V1. In contrast, clockwise typical flutter shows reversed polarity, with broad positive F waves in the inferior leads and a broad, negative, W-shaped deflection in V1. Atrioventricular (AV) conduction in atrial flutter is usually regular but variable, with common ratios of 2:1 (resulting in a ventricular rate of approximately 150 beats per minute), 3:1, or 4:1, depending on AV nodal refractoriness. Higher-degree block or Wenckebach conduction can lead to irregular ventricular responses, potentially mimicking . Rarely, 1:1 conduction occurs, especially under the influence of class IC antiarrhythmic drugs, producing ventricular rates up to 300 beats per minute and resembling . Atypical atrial flutter, which involves circuits independent of the CTI and often arises in the left atrium or due to from prior or , exhibits more variable ECG patterns. F waves may appear broad, polymorphic, or isoelectric in some leads, with lower amplitudes in the inferior leads compared to typical flutter (e.g., approximately 1-1.6 mV versus 2.7 mV in counterclockwise typical cases). Differentiation typically requires invasive electrophysiologic , as surface ECG alone may not reliably distinguish atypical from typical forms. Diagnostic pitfalls include "concealed" flutter, where F waves are not visible due to overlap with QRS complexes or ST segments, particularly at faster ventricular rates, necessitating maneuvers like massage to unmask them. Atrial flutter can also be misdiagnosed as if F waves are subtle or as if AV conduction is highly variable, underscoring the need for careful lead-by-lead analysis and, if needed, administration to reveal underlying atrial activity.

Additional Diagnostic Tests

Echocardiography plays a crucial role in evaluating structural heart disease associated with atrial flutter, including assessment of atrial and ventricular chamber sizes, left ventricular , and valvular abnormalities. Transthoracic is typically the initial modality used to identify underlying conditions such as or reduced ejection fraction that may contribute to the . For patients considered for , transesophageal is recommended to detect left atrial thrombi, as transthoracic approaches have limited sensitivity for this purpose. Laboratory tests are essential to identify reversible triggers and comorbidities in atrial flutter. Serum electrolyte levels, particularly and magnesium, should be measured to detect imbalances that can precipitate or exacerbate the . Thyroid function tests are indicated to rule out , a known precipitant, while renal function assessments help evaluate overall metabolic status and guide potential therapies. Cardiac biomarkers such as may be obtained if ischemic heart disease is suspected as an underlying factor. Holter monitoring or event recorders are employed for patients with paroxysmal atrial flutter or nonspecific symptoms to capture intermittent episodes and correlate them with daily activities. These devices provide continuous or patient-activated electrocardiographic recordings over 24 hours to several weeks, aiding in the detection of triggers or associated arrhythmias. Electrophysiology studies are invasive procedures used to map the reentrant circuits responsible for , particularly in or persistent cases where surface is inconclusive. Catheters are inserted to record intracardiac electrograms, allowing precise localization of the focus for potential planning. Exercise can provoke atrial flutter or reveal ischemia-related triggers, helping differentiate it from other exercise-induced arrhythmias. This test involves monitored physical exertion to assess response and is particularly useful when is a suspected .

Management

Acute Rate and Rhythm Control

Acute management of atrial flutter prioritizes stabilizing the patient by controlling the ventricular rate or restoring , depending on hemodynamic status. For hemodynamically unstable patients exhibiting signs such as or , immediate synchronized electrical is recommended to rapidly restore . In stable patients, initial rate control is often preferred to reduce symptoms and prevent tachycardia-mediated , with rhythm control considered if rate control is ineffective or if symptoms persist. Rate control in acute atrial flutter is achieved primarily through intravenous agents that target atrioventricular nodal conduction. Intravenous beta-blockers, such as metoprolol (starting at 2.5-5 mg every 5 minutes up to 15 mg), are first-line for stable patients without contraindications like severe or , effectively slowing the ventricular response within minutes. Nondihydropyridine , such as (bolus 0.25 mg/kg over 2 minutes followed by infusion), provide rapid rate control in approximately 90% of cases within 24 hours and are suitable for patients with preserved . For patients with or where beta-blockers or are contraindicated, intravenous (total loading dose of 0.5-1 mg IV, given as 0.25 mg increments every 2-6 hours with monitoring for ) is an alternative, though its onset is slower (up to 3 hours) and it is less effective in active or non-hypotensive states. Rhythm control strategies aim to terminate the flutter and restore , particularly in symptomatic or unstable cases. Synchronized using a biphasic at 50-100 J is highly effective (up to 92% success) for acute conversion and is the preferred method for hemodynamically unstable patients, with lower energies often sufficient for atrial flutter compared to . Pharmacological options include intravenous (1 mg over 10 minutes, repeatable once), which achieves conversion in 38-63% of atrial flutter cases within 30-90 minutes and outperforms , though it carries a 2-7% risk of requiring monitoring for 4 hours post-infusion. Intravenous (loading 10-17 mg/kg over 30-60 minutes) is an alternative for stable patients, converting about 14% of cases but associated with in 5-12% and prolongation. Following rhythm control, continuous electrocardiographic monitoring is essential to confirm restoration of and detect complications such as or recurrence. A 12-lead ECG should be obtained immediately post-conversion to assess for underlying abnormalities. Anticoagulation is considered based on flutter duration and risk factors to mitigate , as detailed in specific guidelines.

Anticoagulation Therapy

Anticoagulation is a cornerstone of managing atrial flutter to mitigate the risk of , as atrial flutter carries a similar embolic risk to due to stasis in the left atrial appendage. Risk assessment relies on the CHA₂DS₂-VASc score, which incorporates factors such as congestive (1 point), (1 point), age ≥75 years (2 points), diabetes mellitus (1 point), prior or (2 points), (1 point), age 65-74 years (1 point), and female sex (1 point). Oral anticoagulation is recommended for men with a score of ≥2 or women with a score of ≥3, while should be considered on an individualized basis for men with a score of 1 or women with a score of 2, balancing against bleeding risk assessed via tools like . Direct oral anticoagulants (DOACs), including , , , and , are preferred over antagonists like for most patients with nonvalvular atrial flutter, offering comparable efficacy in preventing or systemic (hazard ratio 0.70; 95% CI, 0.58-0.86) with lower risks of . is reserved for cases involving moderate-to-severe or mechanical heart valves, targeting an international normalized ratio (INR) of 2.0-3.0. In acute settings, such as unscheduled or when rapid anticoagulation is needed, bridging with unfractionated or is initiated until therapeutic levels of oral agents are achieved. The duration of anticoagulation is tailored to clinical context and risk profile: at least 4 weeks before and after to account for atrial stunning, with lifelong therapy recommended for patients with persistent atrial flutter and elevated CHA₂DS₂-VASc scores. Periodic reassessment of and risks is advised, typically every 6-12 months or upon changes in risk factors, to guide continuation or discontinuation. Monitoring involves renal and hepatic function checks for DOACs, with no routine required, whereas necessitates regular INR monitoring to maintain time in therapeutic range above 70%. For complications, reversal strategies include prothrombin complex concentrates for and specific antidotes such as for or for factor Xa inhibitors like and in life-threatening hemorrhage.

Catheter Ablation

Catheter ablation is a curative interventional procedure for atrial flutter that targets the re-entrant circuits responsible for the , primarily by creating lesions to interrupt conduction pathways. For typical atrial flutter, which involves a macro-reentrant circuit around the tricuspid annulus, ablation focuses on the cavotricuspid isthmus (CTI), a critical isthmus of tissue between the and the . This approach is recommended as a first-line rhythm control strategy in symptomatic patients according to the 2023 ACC/AHA/ACCP/HRS Guideline. Indications for include recurrent symptomatic typical atrial flutter refractory to or intolerant of antiarrhythmic drug therapy, as well as patient preference for a potentially curative option over long-term . It is also appropriate for patients with inadequate rate control despite medical management or those with inducible during electrophysiologic study. For atypical atrial flutter, which involves non-CTI-dependent circuits such as those around pulmonary veins or surgical scars, is indicated in cases of drug-refractory recurrence, though it requires more complex mapping. The procedure is typically performed under conscious sedation or general anesthesia in an laboratory. Access is gained via femoral veins, with catheters positioned in the right atrium, , and His bundle region for and pacing. Three-dimensional electroanatomic systems, such as CARTO or EnSite, are used to visualize the atrial and guide lesion delivery, ensuring a linear ablation line across the CTI to achieve bidirectional block, confirmed by pacing maneuvers demonstrating prolonged conduction times. Energy sources include , which delivers to create precise lesions, or , which freezes tissue for safer applications near critical structures; both are effective, with radiofrequency being more commonly used. For atypical flutter, entrainment identifies the circuit, followed by targeted . Uncomplicated cases are often managed as outpatient procedures, lasting 1-3 hours. Outcomes for CTI ablation in typical atrial flutter are excellent, with acute success rates exceeding 95% and long-term freedom from recurrence in 90-95% of patients at 1 year, based on bidirectional achievement. Recurrence rates for typical flutter are low at 5-10%, often due to incomplete lesions, while atypical flutter shows higher variability with 7-53% recurrence depending on . yields comparable results, with chronic success around 91% over 1-5 years. Risks are low overall (2-3% major complications), including atrioventricular (approximately 1%), cardiac perforation or (<1%), and vascular access issues; severe events like or occur in <0.5% of cases. Post-procedure monitoring includes anticoagulation continuation based on risk, as new-onset develops in up to 50% of patients long-term.

Prognosis and Complications

Prognosis

The prognosis of atrial flutter is generally favorable with appropriate , particularly when rhythm control is achieved, resulting in long-term survival rates comparable to those of age-matched individuals without the . In patients undergoing successful , mortality over a mean follow-up of 4 years is approximately 10%, reflecting effective that mitigates associated cardiovascular risks. However, untreated or poorly controlled atrial flutter elevates overall mortality risk by a factor of 1.9 compared to the general population, with comorbidities such as significantly worsening outcomes—doubling the long-term mortality hazard in affected individuals. Recurrence rates for atrial flutter are substantially higher without intervention, ranging from 30% to 50% within the first year, often necessitating ongoing medical therapy or repeated . Catheter markedly reduces this risk, achieving freedom from atrial flutter recurrence in over 90% of cases at 1 year and approximately 73% at 5 years for typical flutter, though forms may see higher rates around 40%. A notable concern is progression to , occurring in 50% to 60% of patients post-ablation within 5 years, with higher rates in those with prior history, driven by underlying atrial substrate changes, which underscores the need for vigilant monitoring. Quality of life in atrial flutter patients improves significantly with rhythm control strategies, including , which alleviates symptoms such as and in the majority, leading to enhanced physical and mental comparable to rate control approaches. Nonetheless, approximately 20% of patients experience persistent symptoms despite optimal therapy, particularly those with comorbid or prior , highlighting the importance of individualized management. Follow-up care involves regular electrocardiographic monitoring, such as annual ECG or Holter assessments, alongside aggressive risk factor modification—including , control, and optimization—to prevent recurrence and atrial remodeling. Due to frequent progression to , patients often require ongoing surveillance and may need anticoagulation indefinitely based on CHA₂DS₂-VASc score, even after successful flutter .

Complications

Atrial flutter predisposes patients to thromboembolic events, primarily due to in the atria leading to clot formation, with an annual or risk of approximately 1.8% in the absence of anticoagulation therapy. This risk is comparable to that in and is quantified by a of 1.4 (95% CI: 1.35–1.46) for compared to individuals in , underscoring the need for risk stratification using tools like the CHA₂DS₂-VASc score. Without preventive anticoagulation, higher-risk patients may face up to 13.9% annual thromboembolic event rates, though this varies by comorbidities. Rapid ventricular rates in atrial flutter can precipitate rate-related complications, including tachycardia-mediated cardiomyopathy, characterized by reversible left ventricular dysfunction from prolonged . This condition arises from incessant rapid rates, leading to impaired systolic function that typically improves with restoration of or adequate rate control. Additionally, uncontrolled rates exacerbate , conferring a fivefold increased risk in affected patients. Other complications include sudden cardiac death, which is rare (less than 1% annually) but elevated twofold overall in atrial flutter patients, particularly those with underlying or rapid conduction. Rapid rates may also induce , especially in individuals with preexisting , through increased left atrial pressures and fluid overload. Procedural interventions carry specific risks; electrical cardioversion without transesophageal echocardiography guidance or prior anticoagulation can result in embolic events in approximately 0.7% to 1% of cases, primarily within the first 48 hours due to atrial stunning. Catheter ablation for atrial flutter, while effective (90% acute success), has an approximately 1% to 2.5% overall complication rate, including cardiac tamponade (<1%) from perforation and stroke or transient ischemic attack (<0.2%). These risks are mitigated by periprocedural anticoagulation and imaging, as detailed in management guidelines.

References

  1. [1]
    What is Atrial Flutter? | American Heart Association
    Mar 26, 2025 · Atrial flutter is a kind of abnormal heart rhythm (arrhythmia). Atrial flutter happens when the upper chambers beat faster than normal and ...
  2. [2]
    Atrial Flutter - StatPearls - NCBI Bookshelf - NIH
    Dec 8, 2022 · Atrial flutter is 1 of the most common arrhythmias. It is characterized by an abnormal cardiac rhythm that is fast, with an atrial rate of 300 beats/min.
  3. [3]
    Atrial flutter - Symptoms and causes - Mayo Clinic
    Aug 29, 2024 · Atrial flutter is a type of heart rhythm disorder, called an arrhythmia. It is similar to atrial fibrillation (AFib).
  4. [4]
    Atrial Flutter: Symptoms & Treatment - Cleveland Clinic
    Atrial flutter is a type of abnormal heart rhythm (arrhythmia) that's too fast. This condition can lead to other problems, like a stroke or heart attack.
  5. [5]
    Atrial Flutter - Cardiovascular Disorders - Merck Manuals
    Atrial flutter is a rapid regular atrial rhythm due to an atrial macroreentrant circuit. Symptoms include palpitations and sometimes weakness.
  6. [6]
    Atrial flutter: Overview of diagnosis and management - UpToDate
    Feb 3, 2025 · INTRODUCTION. Atrial flutter is a cardiac arrhythmia characterized by rapid, regular atrial depolarizations at a characteristic rate of ...
  7. [7]
    Atrial Flutter, Typical and Atypical: A Review
    ### Summary of Atrial Flutter Content
  8. [8]
    Atrial Flutter: Practice Essentials, Background, Pathophysiology
    Jun 14, 2024 · Atrial flutter is a cardiac arrhythmia characterized by atrial rates of 240-400 beats/min, usually with some degree of atrioventricular (AV) node conduction ...Practice Essentials · Background · Pathophysiology · EtiologyMissing: range | Show results with:range<|control11|><|separator|>
  9. [9]
    Global burden and health inequality of atrial fibrillation/atrial flutter ...
    May 20, 2025 · The global age-standardized incidence rate (ASIR) was 52.12 per 100,000 people. Additionally, the prevalence of AF/AFL reached 52,552,045 cases, ...
  10. [10]
    sex differences and global burden projections to 2046—a systematic ...
    Feb 14, 2025 · Research shows that the prevalence of AF/AFL is positively correlated with age, with a particularly pronounced effect in older populations.
  11. [11]
    Global, regional, and national burdens of atrial fibrillation/flutter from ...
    Nov 22, 2023 · Differences in population age composition (developed countries have longer life expectancies, and older people account for a greater proportion) ...
  12. [12]
    Global Burden of Atrial Fibrillation and Flutter by National Income
    Aug 30, 2023 · The global burden of AF/AFL is increasing in all income groups and is more pronounced in middle‐income countries, with further growth to be expected.
  13. [13]
    Atrial flutter: more than just one of a kind - Oxford Academic
    Apr 2, 2015 · Atrial flutter coexists with or precedes AF. In a longitudinal study, AF developed in 56% of patients with lone AFL. ... It has also been shown ...
  14. [14]
    Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications
    ... remodeling: ATR, which occurs with rapid atrial tachyarrhythmias such as AF and atrial flutter, and atrial structural remodeling (ASR), which is associated ...
  15. [15]
    The Atrial Flutter Reentrant Circuit | Circulation
    Atrial reentry around an anatomic barrier with a partially refractory excitable gap: a canine model of atrial flutter.
  16. [16]
    Cavotricuspid Isthmus-Dependent Atrial Flutter. Beyond Simple ...
    Cavotricuspid isthmus (CTI)-dependent atrial flutter is a common cardiac arrhythmia characterized by the occurrence of regular, rapid atrial depolarizations of ...
  17. [17]
    Atrial fibrillation - PMC - NIH
    Conditions that increase atrial size or decrease the wavelength (by decreasing the conduction velocity or refractory period or both) permit multiple wavelets ...
  18. [18]
    Mechanisms of Atrial Fibrillation – Reentry, Rotors and Reality - PMC
    The multiple wavelet hypothesis of AF and the leading circle model of reentry complement each other, as the number of reentrant circuits that can be sustained ...
  19. [19]
    Atrial Flutter | Johns Hopkins Medicine
    the pathway that allows the electrical signal ...
  20. [20]
    Treating Atrial Flutter Symptoms | University of Utah Health
    This results in a normal resting heart rate of 60 to 100 beats per minute. Atrial flutter is a type of arrhythmia (heart rhythm disorder) caused by a “short ...Missing: progression | Show results with:progression<|control11|><|separator|>
  21. [21]
    Atrial Flutter Clinical Presentation: History, Physical Examination
    Jun 14, 2024 · The venous pulsations may be more rapid at the rate of the flutter. Because the AV block may be variable, the pulse may be regular or slightly ...
  22. [22]
    Atrial Flutter, Typical and Atypical: A Review - PMC - PubMed Central
    Clinical electrophysiology has made the traditional classification of rapid atrial rhythms into flutter and tachycardia of little clinical use.
  23. [23]
    Surface Electrocardiographic Characteristics of Right and Left Atrial ...
    All patients showed an ECG pattern characterized by a dominant positive or multiphasic flutter wave in V1 with flat or isoelectric flutter waves in the others ...Right Atrial Afl · Analysis Of The Ecg · Counterclockwise Llr<|control11|><|separator|>
  24. [24]
    Atrial Flutter Workup: Approach Considerations, Electrocardiography ...
    Jun 14, 2024 · A Holter monitor can be used to help identify arrhythmias in patients with nonspecific symptoms, to identify triggers, and to detect associated ...Approach Considerations · Electrocardiography · Diagnostic Aids
  25. [25]
    Atrial flutter - Symptoms, diagnosis and treatment - BMJ Best Practice
    Dec 10, 2024 · Atrial rates are typically above 250 bpm and up to 320 bpm. Ventricular rates range from 120 to 160 bpm, and most characteristically 150 bpm, ...
  26. [26]
    Atrial flutter - Diagnosis and treatment - Mayo Clinic
    Aug 29, 2024 · Electrophysiological (EP) study. This test shows where incorrect heart signals start in the heart. A doctor moves one or more flexible tubes ...
  27. [27]
    2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and ...
    Nov 30, 2023 · The 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation provides recommendations to guide clinicians in the treatment of ...
  28. [28]
    Acute Management of Atrial Fibrillation: Part I. Rate and Rhythm ...
    Jul 15, 2002 · Initial treatment is directed at controlling the ventricular rate, most often with a calcium channel blocker, a beta blocker, or digoxin.
  29. [29]
    Atrial flutter | ACLS-Algorithms.com
    20-50J is commonly enough to revert to sinus rhythm. AHA recommends an initial shock dose 0f 50-100 J for cardioverting unstable atrial flutter.
  30. [30]
    Conversion efficacy and safety of intravenous ibutilide ... - PubMed
    In the patients with atrial flutter, ibutilide had a significantly higher success rate than procainamide (76% [13 of 17] vs. 14% [3 of 22], p=0.001). Similarly, ...
  31. [31]
    Inpatient Management of Acute Atrial Fibrillation and Atrial Flutter in ...
    When parenteral anticoagulation is desired, unfractionated heparin is preferred over low molecular weight heparin. If a patient with AF/AFL also has an ...
  32. [32]
    2020 ACC Expert Consensus Decision Pathway on Management of ...
    Jul 14, 2020 · ∗Reversal/hemostatic agents include repletion strategies such as PCCs, plasma, vitamin K, and specific reversal agents for DOACs (e.g., ...
  33. [33]
    Electrophysiology Study and Ablation of Atrial Flutter - NCBI - NIH
    Jul 8, 2023 · In general, the risks associated with RF ablation are minimal. RF ablation procedures become a highly favorable option when dealing with life- ...
  34. [34]
  35. [35]
    Long term outcome of cavotricuspid isthmus cryoablation for ... - NIH
    This prospective study showed a 91% chronic success rate (range 12 to 60 months) for cryoablation of the CTI in patients with common type AFL.
  36. [36]
    Impact of congestive heart failure and left ventricular systolic function ...
    Atrial fibrillation/atrial flutter is primarily associated with increased in-hospital mortality in heart failure patients. Long-term mortality is increased ...
  37. [37]
    Long-term outcome of patients after successful ... - PubMed
    Freedom from recurrence of typical atrial flutter was 80% at 1 year (95% CIs 72-89%), 73% at 2 years (CIs 63-83%), and 73% at 5 years (CIs 63-83%).Missing: prognosis | Show results with:prognosis
  38. [38]
    Heart failure and atrial flutter: a systematic review of current ... - NIH
    Sep 10, 2021 · We reviewed the incidence, prevalence, and predictors of HF in AFL and vice versa, and the outcomes of treatment of AFL in HF.
  39. [39]
    Quality of life in patients with atrial fibrillation: a systematic review
    This review concluded that quality of life in patients with atrial fibrillation can be significantly improved by both rate and rhythm control strategies.
  40. [40]
    Symptoms and quality of life in patients with coexistent atrial ... - NIH
    Jun 16, 2020 · Patients with coexisting AFL had more often any symptoms than patients with AF only (70% versus 66%, p = 0.04).
  41. [41]
    Risk of thromboembolic events in patients with atrial flutter - PubMed
    A history of embolic events was noted in 11 patients. Acute embolism (<48 hours) occurred in 4 patients (3 after direct current cardioversion, 1 after catheter ...
  42. [42]
    Heart Failure and Sudden Death in Patients With Tachycardia ...
    Tachycardia-induced cardiomyopathy (TIC), a cause of heart failure and impaired left ventricular function, is considered reversible. Left ventricular systolic ...
  43. [43]
    Arrhythmia-Induced Cardiomyopathy: Key Points
    Jun 3, 2024 · AF and atrial flutter with rapid ventricular response are the most common causes, but other arrhythmias also confer risk: atrial tachycardia, ...
  44. [44]
    Contemporary Management of Atrial Flutter | Circulation
    AFl is a macroreentrant arrhythmia; AF is either focally determined or based on multiple reentrant wavelets.